AN OPEN-LABEL, INTRAPATIENT, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ALXN1210 ADMINISTERED INTRAVENOUSLY TO PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: